Cor Vasa 2013, 55(2):e190-e195 | DOI: 10.1016/j.crvasa.2012.11.019

Current opinion on aspirin in primary prevention of atherosclerotic cardiovascular diseases. Is there any difference between diabetic and non-diabetic patients?

Barbora Nussbaumerová*, Hana Rosolová
II. interní klinika, Lékařská fakulta Plzeň, Univerzita Karlova v Praze a Fakultní nemocnice Plzeň, Plzeň, Česká republika

Aspirin reduces vascular death by approximately 15% and nonfatal vascular events by about 30% in secondary prevention. The evidence in primary prevention in non-diabetic subjects is not so powerful. The benefit of aspirin primary prevention in type 2 diabetes remains to be advocated definitely.

Keywords: Aspirin; Cardiovascular disease; Primary prevention; Type 2 diabetes

Received: October 31, 2012; Revised: November 23, 2012; Accepted: November 24, 2012; Published: April 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nussbaumerová B, Rosolová H. Current opinion on aspirin in primary prevention of atherosclerotic cardiovascular diseases. Is there any difference between diabetic and non-diabetic patients? Cor Vasa. 2013;55(2):e190-195. doi: 10.1016/j.crvasa.2012.11.019.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Antiplatelet Trialists' Collaboration, Secondary prevention of vascular events by prolonged antiplatelet therapy, British Medical Journal 296 (1988) 320-331. Go to original source...
    2. C. Hennekens, J.E. Buring, P. Sandercock, et al., Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease, Circulation 80 (1989) 749-756. Go to original source...
    3. V. Fuster, M.L. Dyken, P.S. Vokonas, C. Hennekens, Aspirin as a therapeutic agent in cardiovascular disease, Circulation 87 (1993) 659-675. Go to original source...
    4. Antiplatelet Trialists' Collaboration, Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients, British Medical Journal 308 (1994) 81-106. Go to original source...
    5. Antiplatelet Trialists' Collaboration, Collaborative overview of randomised trials of antiplatelet therapy - II: maintenance of vascular graft or arterial patency by antiplatelet therapy, British Medical Journal 308 (1994) 159-168. Go to original source...
    6. Antithrombotic Trialists' Collaboration, Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, British Medical Journal 324 (2002) 71-86. Go to original source...
    7. J.L. Ferreiro, J.A. Gomez-Hospital, D.J. Angiolillo, Platelet abnormalities in diabetes mellitus, Diabetes and Vascular Disease Research 7 (2010) 251-259. Go to original source... Go to PubMed...
    8. S.H. Alzahrani, R.A. Ajjan, Coagulation and fibrinolysis in diabetes, Diabetes and Vascular Disease Research 7 (2010) 260-273. Go to original source... Go to PubMed...
    9. R. Cífková, S. Býma, R. Češka, et al., Prevence kardiovaskulárních onemocnění v dospělém věku, Cor et Vasa 47 (Suppl) (2005) 3-14.
    10. Steering Committee of the Physicians' Health Study Research Group, Final report on the aspirin component of the ongoing Physicians' Health Study, The New England Journal of Medicine 321 (1989) 129-135.
    11. R. Peto, R. Gray, R. Collins, et al., Randomised trial of prophylactic daily aspirin in British male doctors, British Medical Journal 296 (1988) 313-316. Go to original source...
    12. Medical Research Council's General Practice Research Framework, Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk, Lancet 351 (1998) 233-241. Go to original source...
    13. L. Hansson, A. Zanchetti, S.G. Carruthers, et al., Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial, Lancet 351 (1998) 1755-1762. Go to original source... Go to PubMed...
    14. G. de Gaetano, Collaborative Group of the Primary Prevention Project, Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice, Collaborative Group of the Primary Prevention Project, Lancet 357 (2001) 89-95. Go to original source...
    15. P.M. Ridker, N.R. Cook, I.M. Lee, et al., A randomised trial of low-dose aspirin in the primary prevention of cardiovascular disease in women, The New England Journal of Medicine 352 (2005) 1293-1304. Go to original source... Go to PubMed...
    16. R.S. Eidelman, P.R. Hebert, S.M. Weisman, C.H. Hennekens, An update on aspirin in the primary prevention of cardiovascular disease, Archives of Internal Medicine 263 (2003) 2006-2010. Go to original source... Go to PubMed...
    17. Antithrombotic Trialists' (ATT) Collaboration, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials, Lancet 373 (2009) 1849-1860. Go to original source...
    18. A.A. Bartolucci, M. Tendera, G. Howard, Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin, The American Journal of Cardiology 107 (2011) 1796-1801. Go to original source... Go to PubMed...
    19. S.R. Seshasai, S. Wijesuriya, R. Sivakumaran, et al., Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials, Archives of Internal Medicine 172 (2012) 209-216. Go to original source... Go to PubMed...
    20. M. Sacco, F. Pellegrini, M.C. Roncaglioni, et al., Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial, Diabetes Care 26 (2003) 3264-3272. Go to original source... Go to PubMed...
    21. ETDRS Investigators, Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report, Journal of the American Medical Association 268 (1992) 1292-1300. Go to original source... Go to PubMed...
    22. J. Belch, A. MacCuish, I. Campbell I, et al., The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease, British Medical Journal 337 (2008) a1840. Go to original source... Go to PubMed...
    23. H. Ogawa, M. Nakayama, T. Morimoto, et al., Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial, Journal of the American Medical Association 300 (2008) 2180-2181. Go to original source... Go to PubMed...
    24. Doporučený postup péče o nemocné s diabetes mellitus 2. typu, Diabetologie, metabolismus, endokrinologie, výživa 15 (2012) 13-18.
    25. J. Filipovský, J. Widimský jr., J. Ceral, et al., Diagnostické a léčebné postupy u arteriální hypertenze - verze 2012. Doporučení České společnosti pro hypertenzi, Vnitřní lékařství 58 (2012) 785-801.
    26. M. Pignone, M.J. Alberts, J.A. Colwell, et al., Aspirin for primary prevention of cardiovascular events in people with diabetes, Journal of the American College of Cardiology 55 (2010) 2878-2886. Go to original source... Go to PubMed...
    27. UKPDS Risk Engine. http://www.dtu.ox.ac.uk/riskengine/index.php
    28. ARIC CHD Risk Calculator. http://www.aricnews.net/riskcalc/html/RC1.html
    29. American Diabetes Association Risk Assessment Tool, Diabetes PHD. http://www.diabetes.org/phd
    30. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR), European Heart Journal 33 (2012) 1635-1701. http://dx.doi.org/10.1093/eurheartj/ehs09.
    31. H. Rosolová, B. Nussbaumerová, F. Šefrna, et al., Kardiovaskulární profil, úroveň kontroly a vztah ke komplikacím u diabetiků 2. typu. Závěrečná zpráva projektu podpořeného IGA MZČR NR 8279-3/2005-2007.
    32. B. Petrlová (Nussbaumerová), H. Rosolová, J. Šimon, et al., Kontrola kardiovaskulárních rizikových faktorů u diabetiků 2. typu, Vnitřní lékařství 55 (2009) 812-818.

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes